ଆପିକ୍ସାବାନ

ଆପିକ୍ସାବାନ
Clinical data
Trade names	Eliquis, others
Synonyms	BMS-562247-01
AHFS/Drugs.com	monograph
MedlinePlus	a613032
data	EU EMA: yes; US DailyMed: Apixaban;
Routes of; administration	By mouth
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	~50%
Protein binding	~87%
Metabolism	CYP3A4, CYP3A5, CYP1A2 and others
Elimination half-life	9–14 h
Excretion	Bile (75%), kidney (25%)
Identifiers
	IUPAC name 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide;
ECHA InfoCard	100.167.332
Chemical and physical data
Formula	C25H25N5O4
Molar mass	459.497
3D model (JSmol)	Interactive image;
	SMILES O=C5N(c4ccc(N3C(=O)c1c(c(nn1c2ccc(OC)cc2)C(=O)N)CC3)cc4)CCCC5;
	InChI InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) ; Key:QNZCBYKSOIHPEH-UHFFFAOYSA-N ;
(verify)

ଆପିକ୍ସାବାନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ବେପାର ନାମ ଏଲିକ୍ୱିସ, ଏକ ଆଣ୍ଟିକୋଆଗୁଲାଣ୍ଟ ଔଷଧ ଯାହା ରକ୍ତ ଜମାଟ ବାନ୍ଧିବାକୁ ରୋକିବା ଓ ଚିକିତ୍ସା ପାଇଁ ଦିଆଯାଏ ଏବଂ ଅଣଭାଲୁଲାର୍ ଆଟ୍ରିଆଲ୍ ଫାଇବ୍ରିଲେସନ୍ (AF) ଥିବା ଲୋକଙ୍କଠାରେ ଷ୍ଟ୍ରୋକ୍ ରୋକିବା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୧] ^[୨] ^[୩] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ପୂର୍ବ ଜମାଟ ବାନ୍ଧିବା ଇତିହାସ ଥିବା ରୋଗୀଙ୍କର ହିପ ଓ ଆଣ୍ଠୁ ପ୍ରତିରୋପଣ ଅସ୍ତ୍ରୋପଚାର ପରେ ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା ବନ୍ଦ କରିବା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୪] ଏହା ୱାର୍ଫାରିନର ବିକଳ୍ପ ଭାବରେ ବ୍ୟବହୃତ ହୁଏ ଏବଂ ରକ୍ତ ପରୀକ୍ଷା କରି ଯାଞ୍ଚ କରିବା ଆବଶ୍ୟକ ହୁଏ ନାହିଁ। ^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ | ^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ରକ୍ତସ୍ରାବ ଏବଂ ବାନ୍ତି ହୋଇପାରେ | ^[୧] ^[୨] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ମେରୁଦଣ୍ଡ ଚାରିପାଖରେ ରକ୍ତସ୍ରାବ ଏବଂ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା ହୋଇପାରେ | ^[୪] ଗର୍ଭାବସ୍ଥା କିମ୍ବା ସ୍ତନ୍ୟପାନ ସମୟରେ ବ୍ୟବହାର ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୫] ସାମାନ୍ୟ ବୃକ୍‌କ ସମସ୍ୟାରେ ବ୍ୟବହାର ଅପେକ୍ଷାକୃତ ନିରାପଦ ମନେହୁଏ | ^[୫] ୱାରଫାରିନ ତୁଳନାରେ ଏହାର ଅନ୍ୟାନ୍ୟ ଔଷଧ ସାଥିରେ କମ ପ୍ରତିକ୍ରିୟା ହୁଏ | ^[୬] ଏହା ଏକ ସଳଖ ଫ୍ୟାକ୍ଟର ଏକ୍ସଏ ଇନହିବିଟର । ^[୪]

ମଇ ୨୦୧୧ ମସିହାରେ ୟୁରୋପୀୟ ୟୁନିଅନରେ ଏବଂ ଆମେରିକାରେ ଓ ଡିସେମ୍ଭର୨୦୧୨ ମସିହାରେ ଚିକିତ୍ସା ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୬] ^[୭] ^[୧] ଯୁକ୍ତରାଜ୍ୟରେ ଏହାର ଏକ ମାସର ଯୋଗାଣ ଖର୍ଚ୍ଚ ୨୦୨୦ରେ ୫୩ ପାଉଣ୍ଡ ଥିଲା ।^[୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୪୨୭ ଡଲାର ଅଟେ । ^[୮]୨୯୧୭ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହା ୯୩ତମ ସାଧାରଣତ ପ୍ରେସକ୍ରିପସନ୍ ଔଷଧ ଥିଲା ଯେଉଁଥିରେ ଆଠ ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ରହିଥିଲା।^[୯] ^[୧୦] ଡିସେମ୍ବର ୨୦୧୯ ରେ, ଜେନେରିକ୍ ସଂସ୍କରଣ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଅନୁମୋଦିତ ହୋଇଥିଲା | ^[୩]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ "Apixaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 27 March 2019.
↑ ^୨.୦ ^୨.୧ ^୨.୨ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 133-134. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ ^୩.୦ ^୩.୧ "FDA approves first generics of Eliquis". U.S. Food and Drug Administration (FDA). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Apixaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 27 March 2019.
↑ ^୫.୦ ^୫.୧ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 133-134. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
↑ ^୬.୦ ^୬.୧ Kiser, Kathryn (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. p. 11. ISBN 9783319546438. Archived from the original on 27 March 2019. Retrieved 27 March 2019.
↑ "Eliquis EPAR". European Medicines Agency. Archived from the original on 11 August 2020. Retrieved 22 April 2020.
↑ "Eliquis EPAR". European Medicines Agency. Archived from the original on 11 August 2020. Retrieved 22 April 2020.
↑ "Drug Approval Package: Eliquis (apixaban) NDA #202155". U.S. Food and Drug Administration (FDA). 13 February 2013. Archived from the original on 23 December 2019. Retrieved 23 December 2019.
↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.

[AHFS2019-1] ୧.୦ ^୧.୧ ^୧.୨ "Apixaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 27 March 2019.

[BNF80-2] ୨.୦ ^୨.୧ ^୨.୨ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 133-134. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[FDA_generics-3] ୩.୦ ^୩.୧ "FDA approves first generics of Eliquis". U.S. Food and Drug Administration (FDA). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019.

[autogen1-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ "Apixaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 27 March 2019. Retrieved 27 March 2019.

[autogen2-5] ୫.୦ ^୫.୧ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 133-134. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)

[:0-6] ୬.୦ ^୬.୧ Kiser, Kathryn (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. p. 11. ISBN 9783319546438. Archived from the original on 27 March 2019. Retrieved 27 March 2019.

[Eliquis_EPAR-7] "Eliquis EPAR". European Medicines Agency. Archived from the original on 11 August 2020. Retrieved 22 April 2020.

[Eliquis_EPAR2-8] "Eliquis EPAR". European Medicines Agency. Archived from the original on 11 August 2020. Retrieved 22 April 2020.

[FDA_approval2-9] "Drug Approval Package: Eliquis (apixaban) NDA #202155". U.S. Food and Drug Administration (FDA). 13 February 2013. Archived from the original on 23 December 2019. Retrieved 23 December 2019.

[ref-10] "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]